introduction
Cancer mortality in the European Union (EU), as in North America, has peaked in the late 1980s [1, 2] . From 1988 to 1997 age-standardised total cancer mortality rates felt by 9.3% in men and 8.8% in women. This corresponded to the avoidance of 80 000 deaths per year in the late 1990s in the 15 countries of the former EU, as compared with cancer mortality in the late 1980s [2] .
On the basis of the recent trends in cancer mortality in the 25 countries of the EU, a forecast was proposed for cancer mortality in 2015 of a further fall by 11% in cancer deaths from 2000 to 2015, corresponding to >150 000 fewer deaths per year in 2015 as compared with the rates of 2000 [3] .
Data have now been made available for cancer mortality in Europe up to 2002, allowing a first check of the forecast of further declines in cancer mortality.
patients and methods
We obtained official death certification numbers and population estimates for 24 countries of the EU, except Cyprus, from the World Health Organization database during the period 1980-2002. We recoded all cancer deaths according to the 10th Revision of the International Classification of Diseases, and pooled together all intestinal sites, including rectum, and all uterine cancers (cervix and endometrium). From the matrices of certified deaths and resident populations we computed age-specific rates for each 5-year age group and calendar period, as well as age-standardised rates on the world standard population. Figure 1 gives trends in mortality from the eight major cancer sites in EU men and women during the period 1980-2002. Besides the trends previously described, steady persistent falls original article
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were observed for stomach cancer in both sexes, although stomach cancer is still the fifth cause of death in both sexes combined in the EU, as well as uterine (cervix) in women. Moderate declines were observed over recent years for leukaemias in both sexes, oral cavity, pharynx and oesophagus in men and ovary in women. The only major site showing persisting rise over the last two decades was lung cancer in women whose rate in 2002 (11.4/100 000) was for the first year higher than that for intestinal cancer (11.1/100 000). Thus, lung cancer is now the second site of cancer deaths in European women following breast (17.9/100 000), and the annual rate of increase has been larger over the last 5 years (+1.85%) as compared with the previous decade (+1.36%).
discussion
Despite the persisting rises in female lung cancer due to spread of tobacco smoking among European women after the second World War, and mainly since the early 1970s [4, 5] , the recent trends in cancer mortality in the EU remain favourable, with a >5% fall in both sexes over the last 5 years. In men, about 40% of the decline is due to lung cancer alone, and at least an additional 10% to other tobacco-related cancers, following the decreased prevalence of tobacco smoking in European men over the last decades [4] . About 15% of the fall is still due to the persisting decline of gastric cancer, and other relevant contributions are due to recent falls in colorectal and prostate cancers.
In women, the largest contributions to the fall in cancer mortality are due to breast and colorectum, indicating that the advancements are largely attributable to improved diagnosis, and mostly treatment of breast cancer [6] [7] [8] .
The most recent trends in cancer mortality in Europe are thus encouraging and indicate that the forecast of 11% reduction in cancer mortality from 2000 to 2015 is realistic and possible. In fact, a linear extrapolation of a fall by 1.13% per year would correspond to a 16% decrease over a 15-year period. In terms of total numbers of cancer deaths, this would correspond to 1.2 million deaths in 2015 in the EU, as compared with about 1.1 million in 2002, and to 1.4 million in 2015 in the absence of continuing falls in rates.
Further control of tobacco, and consequently of tobaccorelated cancer mortality, remains a priority not only for men but also for women. Widespread and uniform adoption across Europe of advanced screening diagnostic and therapeutic approaches is also urgent to reduce the burden of cancer mortality in the EU [9, 10] . references
